“GreenLight strives to address humanity’s greatest challenges, from vaccine production to protecting bees,” said Andrey Zarur, CEO of GreenLight. “Mark brings the experience and expertise we need to move forward towards our goal of feeding the world’s growing population while protecting the planet.”
Singleton will report to Andrey Zarur and lead phytosanitary innovations such as GS2, GreenLight’s RNA-based Colorado potato beetle control product.
Founded in 2008, GreenLight has raised $ 230 million to date and is rapidly expanding into new market opportunities in the areas of human, animal and plant health. Last year, GreenLight raised more than $ 100 million in an oversubscribed Series D cycle to accelerate efforts around a COVID-19 vaccine and the manufacture of messenger RNA.
The main investors are Morningside, Baird Capital, Cormorant Asset Management, Fall Line, S2G Ventures, Lupa Systems Capital,…
News Highlights Finance
- Headline: GreenLight Biosciences Welcomes Mark Singleton as Innovation Leader in Plant Health
- Check all news and articles from the Health news information updates.